Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.

Gandhi, Leena

Gandhi, Leena.

Affiliation

Gandhi L; NYU School of Medicine and Perlmutter Cancer Center, New York, New York.

Clin Adv Hematol Oncol ; 16(7): 484-485, 2018 Jul.

Article in En | MEDLINE | ID: mdl-30067619

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/immunology; Clinical Trials as Topic; Drug Design; ErbB Receptors/genetics; Humans; Lung Neoplasms/genetics; Lung Neoplasms/immunology; Molecular Targeted Therapy; Multicenter Studies as Topic; Pemetrexed/administration & dosage; Platinum/administration & dosage; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases/genetics; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Clin Adv Hematol Oncol Year: 2018 Document type: Article

Search on Google

XML

PubMed Links